Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

Cyclophosphamide 26Rituximab 22Biopsy 17Specimen Handling 16Prednisone 15Magnetic Resonance Spectroscopy 14Doxorubicin 14fludarabine 12Vincristine 12fludarabine phosphate 9Etoposide 7Bendamustine Hydrochloride 7Tacrolimus 6Nuclear Medicine Department, Hospital 6Melphalan 6trametinib 5acalabrutinib 5X-Rays 5Whole-Body Irradiation 5Radiotherapy 5Mycophenolic Acid 5Lenalidomide 5Crizotinib 5pembrolizumab 4ibrutinib 4copanlisib 4Prednisolone 4Mesna 4Dexamethasone 4Cytarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma × Biological Products × Clear all
NCT01430390 2025-06-11

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
19 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡